Syndax Pharmaceuticals (SNDX) News
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
8.72-0.41 (-4.49%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SNDX news summary
We found 24 recent headlines mentioning Syndax Pharmaceuticals (SNDX): 0 in the past week and 13 in the past 30 days, most often from GlobeNewswire, Nasdaq, PR Newswire. For price context, SNDX is down 4.49% at $8.72. The most recent story, "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX", was published by PR Newswire on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Syndax Pharmaceuticals headlines
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXNEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are…PR Newswire
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in…GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are…PR Newswire
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November…GlobeNewswire
- Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company…GlobeNewswire
- Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo Growth(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX) reported a narrower third-quarter loss as revenue from both commercial products increased.NasdaqINCY, SNDX, SUN
- Syndax (SNDX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -GlobeNewswire
- Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –GlobeNewswire
- Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -GlobeNewswire
- Syndax Announces Participation in November Investor ConferencesNEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.…GlobeNewswire
- Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseSyndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqSNDX, INCY
- Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will…GlobeNewswire
- Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 ListNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ®…GlobeNewswire
- Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalSNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.NasdaqSNDX, AMRN, CORT, ALDX
- Stocks Finish Lower Ahead of Wednesday’s CPI ReportThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%.…NasdaqAMAT, MPC, RARE, CVX
- Tuesday Sector Laggards: Biotechnology, Metals & Mining StocksIn trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Syndax Pharmaceuticals, off about 17% and shares of…NasdaqSNDX, GLSI, AREC, IDR
- Stocks Decline as Chipmakers RetreatThe S&P 500 Index ($SPX ) (SPY ) is down by -0.13% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.59%. December E-mini…NasdaqAMAT, SNDK, INTU, JNJ
- Stocks Mixed on Lower Crude Prices and Weakness in ChipmakersThe S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.37%. December E-mini S&P…NasdaqAMAT, SNDK, INTU, DDOG
- Why is Syndax Pharmaceuticals stock sliding today?Investing.com
- Syndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate…NasdaqSNDX, ET
- Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate…Nasdaq
- Syndax Pharmaceuticals stock tumbles on failed IPF trialInvesting.com
- Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis– Trial did not meet the primary endpoint of annualized rate of FVC decline –GlobeNewswire